frankdev
@frankdev Bought $HIMS @33.55
Spain
๐™ƒ๐™ž๐™ข๐™จ & ๐™ƒ๐™š๐™ง๐™จ: ๐™Œ๐™ช๐™ž๐™˜๐™  ๐˜ฟ๐™š๐™˜๐™ž๐™จ๐™ž๐™ค๐™ฃ ๐™‚๐™ช๐™ž๐™™๐™š Iโ€™ve just opened a position in Hims & Hers ($HIMS (Hims & Hers Health Inc)), using 1.05% of my equity at $33.32. Hereโ€™s a concise look at the pros and cons of this telehealth innovator: ๐Ÿฑ ๐—ฅ๐—ฒ๐—ฎ๐˜€๐—ผ๐—ป๐˜€ ๐˜๐—ผ ๐—•๐˜‚๐˜† โ€ข Rapid Growth โ€“ In 2024, revenue soared 69% to nearly $1.5B, and subscribers reached 2.2M. Strong growth is expected to continue into 2025. โ€ข Improving Profits โ€“ The companyโ€™s Adjusted EBITDA is rising fast, and they achieved positive free cash flow in Q4 2024. โ€ข Market Leader โ€“ Hims & Hers holds a leading position in the expanding telehealth market. โ€ข Smart Expansion โ€“ Strategic moves into weight loss, lab diagnostics, and personalized treatments demonstrate effective diversification. โ€ข Strong Finances โ€“ The balance sheet boasts significant cash and zero debt. ๐Ÿฎ ๐—ฅ๐—ฒ๐—ฎ๐˜€๐—ผ๐—ป๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—–๐—ฎ๐˜‚๐˜๐—ถ๐—ผ๐—ป โ€ข Regulatory Changes โ€“ Evolving rules in telehealth and pharma (e.g., the FDAโ€™s stance on semaglutide) may pose challenges. โ€ข Stock Volatility โ€“ Hims & Hers can experience significant price swings, which might not suit every risk profile. ๐—•๐—ผ๐˜๐˜๐—ผ๐—บ ๐—Ÿ๐—ถ๐—ป๐—ฒ: Hims & Hers offers rapid growth and solid financials, but keep an eye on regulatory hurdles and potential stock volatility. If you believe in the long-term potential of telehealth, $HIMS (Hims & Hers Health Inc) could be a compelling addition to your portfolio. #HimsAndHers #Telehealth #Investing #GrowthStocks #LongTermInvestment
HIMS
Hims & Hers Health Inc
55.35
-1.67 (-2.92%)
Like CommentShare
null
.